Europe
At the 26th United European Gastroenterology Week (UEGW) congress in Vienna, Janssen presented three-year data from the IM-UNITI study, which demonstrates the continued efficacy of Stelara (ustekinumab) in improving clinical remission rates.
A prostate cancer drug jointly developed by healthcare giant Bayer and Finland-based Orion can slow the spread of the disease, according to late-stage study results announced early Wednesday.
Combioxin SA announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.
BioArctic AB announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain.
Osteoarthritis is a disabling disease characterised by joint pain and restricted mobility, affecting especially the elderly.
LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.
The survey provides latest insights into the status quo and future of drug product formulation and its potential to refine all steps in the biopharmaceutical value chain.
Apogenix announced today that company representatives will attend several upcoming international conferences. In a total of five presentations, Apogenix will give updates on its hexavalent TNF superfamily receptor agonists (HERA-ligands) as well as its phase III-ready lead drug candidate asunercept.
Crescendo Biologics Ltd today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
PRESS RELEASES